Chong Kun Dang Pharmaceutical Corporation

Inje University Industry-Academic Cooperation Foundation

Nina Ha

Daekwon Bae

Soyoung Kim

Hyeseung Song

ChangSik Lee

Changsik Lee

Miseon Bae

Hyun-Mo Yang

Hyojin Lim

Hojin Choi

Jaewon Lee

Jihyun Kim

Yuntae Kim

Jaeyoung Lee

Dohoon Kim

Jaeki Min

Jaekwang Lee

Young Il Choi

Daekyu Choi

Su Kil Seo

Suyeal Bae

Sera Lee

SunMi Lee

Il Hyang Kim

Ilhyang Kim

Jungtaek Oh

Changkon Lee

Seongae Yoon

Eunhee Ko

Dalyong Kwak

Changgon Lee

Youngil Choi

Seohee Lee

Song-Min Lee

Sunmi Lee

The present invention relates to a pharmaceutical composition for preventing or treating lupus, containing a compound represented by a formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an effective component, as well as a treatment method using the compound, and use of the compound in the manufacture of a medicament for treating lupus. The pharmaceutical composition according to the present invention shows an excellent effect of preventing or treating lupus.

Compositions for preventing or treating lupus

A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity, wherein X, Q, N, R, R, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Provided are urea derivatives of Formula I: with histone deacetylase (HDAC) inhibitory activity, optical isomers thereof, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. The provided urea derivatives of Formula I are selective histone deacetylase (HDAC) inhibitors and are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, and neurodegeneration.

Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same

The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.

Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same

Growing community of inventors

Gyeonggi-do, South Korea

Nina Ha